OBJETIVO: Caracterizar o usuário de medicamentos, especialmente aquele que se automedica. MATERIAL E MÉTODO: Foram entrevistadas 413 pessoas do Município de Santa Maria, Estado do Rio Grande do Sul, Brasil, sobre o consumo de medicamentos no último mês. RESULTADOS: Dos entrevistados, 69,9% utilizaram medicamentos e destes 76,1% o fizeram através de automedicação. Cefaléia (28,8%) foi a principal queixa motivadora de automedicação. O ácido acetilsalicílico foi a droga mais utilizada (25,4%). Dos fármacos utilizados na automedicação, 51,2% foram indicados por terceiros e 51,7% dessas indicações eram prescrições médicas emitidas em consultas anteriores. CONCLUSÃO: Idade, grau de escolaridade e acompanhamento médico periódico correlacionaram-se significativamente com automedicação.

Accumulating evidence suggests that corticotropin-releasing hormone (CRH) neurocircuitry modulate the neuroendocrine and behavioural phenotypes in depression and anxiety. Thus, the administration of the selective CRH-receptor 1 (CRHR1)-antagonist R121919/NBI 30775 has proven its ability to act as an anxiolytic in rats. It is still unclear whether vasopressinergic neuronal circuits, which are known to be involved in the regulation of emotionality, are affected by R121919/NBI 30775. Using DBA/2OlaHsd mice, we investigated the effects of chronic social defeat and concomitant treatment with R121919/NBI 30775 on 1) the behavioural profile in the modified hole board test and 2) in-situ hybridization analysis-based expression of arginine vasopressin (AVP) and CRH mRNA in both the hypothalamic paraventricular nucleus and supraoptic nucleus. The results suggest that chronic social defeat leads to increased avoidance behaviour and reduction in directed exploration, general exploration, and locomotion. Chronic treatment with the CRHR1-antagonist was effective in reversing the directed exploration to control level. The dissection of the antagonist-treated group into responders and non-responders using the parameter time spent on board revealed further positive effects of R121919/NBI 30775 on avoidance behaviour and locomotion. Behavioural changes were accompanied by alterations in AVP gene expression in the paraventricular nucleus. Taken together, the anxiolytic action of the CRHR1 antagonist was found in a subgroup of animals only, and further studies have to be done to clarify the interindividual biological differences in response patterns to this compound to optimise its application under clinical conditions.

No abstract

No abstract